Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Valpromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.56 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.55 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.55 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.55 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.55 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.55 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.55 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.55 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 2/20 | 0.48 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.34 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valpromide SCHEMBL35392 | 0.97 | CA2 (0.58) | CA2CA1HDAC1HDAC2CHRM1 | |
| Valpromide SCHEMBL28307837 | 0.94 | CA2 (0.56) | CA2CA1HDAC1HDAC2CHRM1 | |
| Valpromide SCHEMBL30601110 | 0.94 | CA2 (0.56) | CA2CA1HDAC1HDAC2CHRM1 | |
| Hydrochloric Acid SCHEMBL28806599 | 0.91 | CA2 (0.72) | CA2CA1HDAC1HDAC2CHRM1 | |
| Hydrochloric Acid SCHEMBL17748959 | 0.90 | CA2 (0.71) | CA2CA1HDAC1HDAC2CHRM1 | |
| SCHEMBL6947583 | 0.87 | CA2 (0.75) | CA2CA1HDAC1HDAC2CHRM1 | |
| SCHEMBL3349103 | 0.87 | CA2 (0.75) | CA2CA1HDAC1HDAC2CHRM1 | |
| SCHEMBL10776270 | 0.87 | CA2 (0.50) | CA2CA1HDAC1HDAC2CHRM1 | |
| SCHEMBL7859211 | 0.87 | CA2 (0.50) | CA2CA1HDAC1HDAC2CHRM1 | |
| Valproic Acid SCHEMBL3336542 | 0.87 | CHRM1 (0.76) | CA2CA1HDAC1HDAC2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234496-A | Improved treatment of advanced/metastatic cancers with checkpoint inhibitor resistance or drug resistance susceptibility | 海南先声再明医药股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118085109-A | Immunomodulatory compounds | 昆士兰医学研究所理事会 | 2024-05-28 | — | — | CN | disclosed |
| CN-114456164-B | Pesticidally active heterocyclic derivatives with sulphur and hydroxylamine substituents | 先正达参股股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117562905-A | Maintenance of immune response during chemotherapy regimen | G1治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117530948-A | Maintenance of immune response during chemotherapy regimen | G1治疗公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-111108107-B | Pesticidally active heterocyclic derivatives with sulfur containing substituents | 先正达参股股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116804010-A | Pesticidally active heterocyclic derivatives with sulfur containing substituents | 先正达参股股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116710130-A | Protein 2 antibodies containing motile sperm domains and methods of use thereof | 脉管生物生长有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-110312707-B | Pesticidally active heterocyclic derivatives with sulfur containing substituents | 先正达参股股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-104854092-B | Pyridine-2-amides useful as CB2 agonists | 霍夫曼-拉罗奇有限公司 | 2018-08-10 | — | — | CN | disclosed |
| US-20150157600-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-20150157599-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-20150157601-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-9051240-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-09 | — | — | US | disclosed |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-31 | — | — | US | disclosed |
| US-20130274249-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-17 | — | — | US | disclosed |
| US-8519000-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-08-27 | — | — | US | disclosed |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-19 | — | — | US | disclosed |
| EP-0700383-A1 | NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS | SYNTEX (U.S.A.) INC. (US) | 1996-03-13 | — | — | EP | disclosed |
| EP-0205362-A1 | Quinolyl glycinamide derivatives, process for their preparation and their pharmaceutical use as psychotropes | SANOFI (FR) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274249-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | CA2 56/4885HDAC1 660/4885HDAC2 211/4885 |
| US-20150157601-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1E, CACNA1S | CA2 76/4885HDAC1 880/4885HDAC2 443/4885 |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | CA2 51/4885HDAC1 653/4885HDAC2 204/4885 |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | CA2 56/4885HDAC1 660/4885HDAC2 211/4885 |
| US-20150157600-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1E, CACNA1S | CA2 76/4885HDAC1 880/4885HDAC2 443/4885 |
| US-20150157599-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1E, CACNA1S | CA2 76/4885HDAC1 880/4885HDAC2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.